Pyoderma Gangraenosum (PG)

• InflaRx's lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including Pyoderma Gangraenosum (PG), a rare ulcerative skin disorder.
• InflaRx recently released positive interim results from three cohorts in its’ Phase II clinical study to investigate a potential benefit of vilobelimab for patients suffering from PG. In Q4’21, this study completed its treatment period with the observation period to be completed in the 1H’22.
• Read more here.

Critical COVID-19

• InflaRx's lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including critical COVID-19.
• The program is being funded by grants from the German Ministry of Research and Education along with the German Ministry of Health.
• For more information about this trial, please visit www.clinicaltrials.gov or click here.
• Additional information about COVID-19 and data to date with vilobelimab in this indication can be found here.

PD-1 or PD-L1 inhibitor Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)

• InflaRx has entered into a clinical collaboration agreement with Merck & Co, Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada) to evaluate the combination of vilobelimab and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with a PD-1 or PD-L1 inhibitor Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC). In June 2021, the first patient was dosed in a Phase IIa clinical study with two vilobelimab arms, including one with KEYTRUDA®.
• KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, U.S.A, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
• Read more here

IFX-2

• IFX-2 is an advancement of vilobelimab technology, in preclinical development. IFX-2 is a highly potent anti-complement C5a antibody with a higher humanization grade and altered pharmacokinetic properties.
• IFX-2 was developed to target chronic inflammatory diseases with high unmet medical need. Recent scientific publications suggest a fundamental role of the complement factor C5a for various neutrophil driven diseases but also for the disturbance of the T-cell homeostasis, thereby contributing to mechanisms involved in chronic and autoimmune inflammatory diseases. Therapies blocking the C5a / C5aR axis are believed to induce regulatory T-cell generation and decrease Th17- and Th1- type responses. Thus, a therapeutic anti-C5a approach would be applicable within a large variety of T-cell driven inflammatory diseases.

IFX-2